Trial
NCT05394350
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Advanced Solid Tumors
Intervention
MK-1088
Why stopped
Business Reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-08